A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Inclusion Criteria:

• All females must have a negative pregnancy test at the Screening Visit and onadmission to the Clinical Unit.

• Females of childbearing potential must not be lactating and if heterosexually activemust agree to use an approved method of highly effective contraception.

• Females of non-childbearing potential must be confirmed at the Screening Visit.

• Sexually active fertile male participants with partners of childbearing potentialmust adhere to the contraception methods.

• Have a BMI between 18 and 32 kg/m2 inclusive at both Screening and Admission andweigh at least 45 kg at Screening.

• For healthy Japanese cohorts (Part A2 and Part B2): healthy male and femaleparticipants are to be Japanese, defined as having both parents and 4 grandparentswho are Japanese. This includes second and third generation participants of Japanesedescent whose parents or grandparents are living in a country other than Japan.

• For healthy Chinese cohort (Part A3): healthy male and female Chinese participantsfor whom both parents and all grandparents are Chinese and not lived outside ofChina for more than 10 years.

Exclusion Criteria:

• History of any clinically important disease or disorder or presence ofgastrointestinal, hepatic, or renal disease or any other condition known tointerfere with absorption, distribution, metabolism, or excretion of drugs.

• Any clinically important illness, medical/surgical procedure, or trauma.

• Clinically significant serious active and chronic infections.

• Any history or evidence of TB (active or latent).

• Known history of primary immunodeficiency (congenital or acquired) or an underlyingcondition that predisposes to infection.

• Bacillus Calmette Guérin vaccine within one year prior to signing the ICF.

• Any abnormal laboratory values at the Screening Visit or on Admission to theClinical Unit.

• Any positive result on Screening for serum Hepatitis B surface antigen (HBsAg),anti-Hepatitis B core (HBc), hepatitis C antibody, or Human immunodeficiency virus (HIV).

• Any clinically important abnormalities in ECG.

• History of severe allergy/hypersensitivity or ongoing clinically importantallergy/hypersensitivity.

• Known hypersensitivity to furosemide and rosuvastatin (for Part C only)

• History of alcohol abuse or excessive intake of alcohol or current smokers or thosewho have smoked or used nicotine products.

• Use of drugs with enzyme inducing properties or of any prescribed or nonprescribedmedication or of systemic hormonal contraceptives.

• Clinical signs and symptoms consistent with COVID-19.